| [X] | QUARTERLY                REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES                EXCHANGE ACT OF 1934 |
|-----|-----------------------------------------------------------------------------------------------------------------------|

| [                ] | TRANSITION                REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES                EXCHANGE ACT OF 1934 |
|------------------------------|------------------------------------------------------------------------------------------------------------------------|

----

| Delaware                                                         |   | 91-1549305                          |
|-----------------------------------------------------------------------|--------|------------------------------------------|
| (State                or other                jurisdiction       |   | (I.R.S.                Employer     |
| of                incorporation or                organization)  |   | Identification                No.)  |

----

**Explanatory      Note**

----

|                                          | PAGE                                                                                                                                          |
|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| PART                  I FINANCIAL INFORMATION |                                                                                                                                               |
|                                          |                                                                                                                                               |   |
| Item                  1.                      | Financial                  Statements                                                                                                              |   |
|                                          |                                                                                                                                               |   |
|                                          | Balance                  sheets - June 30, 2005 (unaudited) and December 31, 2004                                                                  | 4 |
|                                          |                                                                                                                                               |   |
|                                          | Statements                  of Operations - Three Months and Six Months Ended June 30, 2005                  and 2004                  (unaudited) | 5 |
|                                          |                                                                                                                                               |   |
|                                          | Statements                  of Cash Flows- Six Months Ended June 30, 2005 and 2004                  (unaudited)                                    | 6 |
|                                          |                                                                                                                                               |   |
|                                          | Notes                  to Financial Statements (unaudited)                                                                                         | 7 |
|                                          |                                                                                                                                               |   |
| Item                  2.                 | Management's                    Discussion and Analysis of Financial Condition And Plan of                    Operation                            | 17 |
|                                          |                                                                                                                                               |   |
| Item                  3.                      | Controls                  and Procedures                                                                                                           | 25 |
|                                          |                                                                                                                                               |   |
| PART                  II OTHER INFORMATION    |                                                                                                                                               |
|                                          |                                                                                                                                               |   |
| Item                  1.                      | Legal                  Proceedings                                                                                                                 | 26 |
|                                          |                                                                                                                                               |   |
| Item                  2.                      | Changes                  in Securities                                                                                                             | 26 |
|                                          |                                                                                                                                               |   |
| Item                  3.                      | Defaults                  Upon Senior Securities                                                                                                   | 26 |
|                                          |                                                                                                                                               |   |
| Item                  4.                      | Submission                  of Matters to a Vote of Security Holders                                                                               | 26 |
|                                          |                                                                                                                                               |   |
| Item                  5.                      | Other                  Information                                                                                                                 | 26 |
|                                          |                                                                                                                                               |   |
| Item                  6.                      | Exhibits                                                                                                                                           | 27 |
|                                          |                                                                                                                                               |   |
| Signatures.                                   |                                                                                                                                               | 28  |
|                                          |                                                                                                                                               |   |
| Certifications                                |                                                                                                                                               | 29  |

----

**PART      I FINANCIAL INFORMATION**

**Item      1. FINANCIAL STATEMENTS**

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS, INC.**

**BALANCE      SHEETS**

|                                                                                                                                                                             |   |   |  **June                30, 2005** |   |   |  **December 31, 2004** |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----------------------------------------|--------|--------|---------------------------------------|--------|
|                                                                                                                                                                             |   |   |  **(Unaudited)**                  |   |   |                                  |   |
|                                                                                                                                                                             |   |   |  **(Restated)**                   |   |   |                                  |   |
|                                                                                                                                                                             |   |   |                                   |   |   |                                  |   |
| **ASSETS**                                                                                                                                                                  |   |   |                                   |   |   |                                  |   |
|                                                                                                                                                                             |   |   |                                   |   |   |                                  |   |
| CURRENT                ASSETS:                                                                                                                                                   |   |   |                                        |   |   |                                       |   |
| Cash                and cash equivalents                                                                                                                                         |   | $      | 308,122                                |   | $      | 148,630                               |   |
| Accounts                receivable, net of allowance for doubtful accounts of $107,477 and                $                55,495 for both 2005 and 2004                         |   |   | 52,703                                 |   |   | 248,279                               |   |
| Inventories                                                                                                                                                                      |   |   | 88,967                                 |   |   | 102,027                               |   |
| Prepaid                expenses                                                                                                                                                  |   |   | 10,726                                 |   |   | —                               |   |
|                                                                                                                                                                             |   |   |                                   |   |   |                                  |   |
| Total                current assets                                                                                                                                              |   |   | 460,518                                |   |   | 498,936                               |   |
|                                                                                                                                                                             |   |   |                                        |   |   |                                       |   |
| Property                and equipment, net of accumulated depreciation of $538,672 (2005)                and                $518,675(2004)                                       |   |   | 114,711                                |   |   | 73,269                                |   |
| Equipment                under construction                                                                                                                                      |   |   | 664,401                                |   |   | 603,111                               |   |
| Patents                and trademarks, net of accumulated amortization of $120,503                (2005)                 and                $115,220 (2004)                 |   |   | 58,363                                 |   |   | 62,046                                |   |
| Deferred                costs, less accumulated amortization of $198,743 (2005)                and                $141,600 (2004)                                                |   |   | 273,257                                |   |   | 170,400                               |   |
| Deposits                                                                                                                                                                         |   |   | 13,500                                 |   |   | 800                                   |   |
|                                                                                                                                                                             |   |   |                                   |   |   |                                  |   |
|  TOTAL                ASSETS                                                                                                                                                |   | $      | 1,584,750                              |   | $      | 1,408,562                             |   |
|                                                                                                                                                                             |   |   |                                   |   |   |                                  |   |
| **LIABILITIES                AND SHAREHOLDERS’ EQUITY**                                                                                                                    |   |   |                                        |   |   |                                       |   |
|                                                                                                                                                                             |   |   |                                        |   |   |                                       |   |
| CURRENT                LIABILITIES:                                                                                                                                              |   |   |                                        |   |   |                                       |   |
| Bank                overdraft                                                                                                                                                    |   | $      | —                                |   | $      | 26,953                                |   |
| Note                payable - shareholders                                                                                                                                       |   |   | 6,624                                  |   |   | 243,398                               |   |
| Accounts                payable                                                                                                                                                  |   |   | 37,384                                 |   |   | 129,222                               |   |
| Customer                advances                                                                                                                                                 |   |   | 13,955                                 |   |   | 18,465                                |   |
| Accrued                expenses                                                                                                                                                  |   |   | 185,350                                |   |   | 356,081                               |   |
| Accrued                payroll expense to officers                                                                                                                               |   |   | 181,293                                |   |   | 161,250                               |   |
| Payroll                and payroll taxes payable                                                                                                                                 |   |   | 118,261                                |   |   | 70,078                                |   |
|                                                                                                                                                                             |   |   |                                   |   |   |                                  |   |
| Total                current liabilities                                                                                                                                         |   |   | 542,867                                |   |   | 1,005,447                             |   |
|                                                                                                                                                                             |   |   |                                   |   |   |                                  |   |
| LONG-TERM                DEBT                                                                                                                                                    |   |   |                                   |   |   |                                  |   |
| Debentures                payable-net of discount                                                                                                                                |   |   | 85,140                                 |   |   | —                               |   |
| Note                payable - shareholder                                                                                                                                        |   |   | 1,932,099                              |   |   | 2,069,839                             |   |
|                                                                                                                                                                             |   |   |                                   |   |   |                                  |   |
| TOTAL                LIABILITIES                                                                                                                                                 |   |   | 2,560,106                              |   |   | 3,075,286                             |   |
|                                                                                                                                                                             |   |   |                                   |   |   |                                  |   |
| COMMITMENTS                AND CONTINGENCIES                                                                                                                                     |   |   |                                        |   |   |                                       |   |
|                                                                                                                                                                             |   |   |                                        |   |   |                                       |   |
| SHAREHOLDERS’                DEFICIT:                                                                                                                                      |   |   |                                   |   |   |                                  |   |
| Series                1998-B Convertible Preferred Stock: 1,645 shares authorized, none                issued                and outstanding                                     |   |   | —                                |   |   | —                               |   |
| Common                stock, $.001 par value, 50,000,000 shares authorized, issued and                outstanding: 31,709,491 shares (2005) and 30,509,491                (2004) |   |   | 31,709                                 |   |   | 30,509                                |   |
| Additional                paid-in capital                                                                                                                                        |   |   | 44,945,978                             |   |   | 42,073,056                            |   |
|  Less:                Deferred compensation                                                                                                                                 |   |   | (399,191                               | )      |   | —                               |   |
| Accumulated                deficit                                                                                                                                               |   |   | (45,553,852                            | )      |   | (43,770,289                           | )      |
|                                                                                                                                                                             |   |   |                                   |   |   |                                  |   |
| TOTAL                SHAREHOLDERS’ DEFICIT                                                                                                                                 |   |   | (975,356                               | )      |   | (1,666,724                            | )      |
|                                                                                                                                                                             |   |   |                                   |   |   |                                  |   |
|  TOTAL                LIABILITIES AND SHAREHOLDERS’                DEFICIT                                                                                            |   | $      | 1,584,750                              |   | $      | 1,408,562                             |   |

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS, INC.**

**STATEMENTS      OF OPERATIONS**

**(Unaudited)**

|                                                             |   |   |  **Three                Months Ended June 30,** |   |   |  **Six                Months Ended June 30,** |   |
|------------------------------------------------------------------|--------|--------|------------------------------------------------------|--------|--------|----------------------------------------------------|--------|
|                                                             |   |   |                                                 |   |   |                                               |   |
|                                                             |   |   |  **2005**                                       |   |   |  **2004**                                     |   |   |  **2005** |   |   |  **2004** |   |
|                                                             |   |   |  RESTATED                                       |   |   |                                               |   |   |  RESTATED |   |   |   |   |
| REVENUES:                                                        |   |   |                                                      |   |   |                                                    |   |   |  |   |   |  |   |
| Product                Sales                                     |   | $      | 176,534                                              |   | $      | 375,362                                            |   | $ | 441,007 |   | $ | 655,560 |   |
| Royalty                Income                                    |   |   | -                                                    |   |   | -                                                  |   |   | 546 |   |   | 921 |   |
|                                                             |   |   |                                                 |   |   |                                               |   |   |   |   |   |   |   |
|                                                             |   |   | 176,534                                              |   |   | 375,362                                            |   |   | 441,553 |   |   | 656,481 |   |
| COST                OF PRODUCTS SOLD                             |   |   | 56,394                                               |   |   | 167,946                                            |   |   | 150,740 |   |   | 241,263 |   |
|                                                             |   |   |                                                 |   |   |                                               |   |   |   |   |   |   |   |
| Gross                profit                                      |   |   | 120,140                                              |   |   | 207,416                                            |   |   | 290,813 |   |   | 415,218 |   |
|                                                             |   |   |                                                 |   |   |                                               |   |   |   |   |   |   |   |
| OPERATING                EXPENSES:                               |   |   |                                                      |   |   |                                                    |   |   |  |   |   |  |   |
| Research                and development                          |   |   | 84,556                                               |   |   | 155,000                                            |   |   | 161,556 |   |   | 365,000 |   |
| Selling,                general and administrative               |   |   | 633,070                                              |   |   | 79,018                                             |   |   | 1,616,824 |   |   | 152,060 |   |
|                                                             |   |   |                                                 |   |   |                                               |   |   |   |   |   |   |   |
|                                                             |   |   | 717,626                                              |   |   | 234,018                                            |   |   | 1,778,380 |   |   | 517,060 |   |
|                                                             |   |   |                                                 |   |   |                                               |   |   |   |   |   |   |   |
| Loss                from operations                              |   |   | (597,486                                             | )      |   | (26,602                                            | )      |   | (1,487,567 | ) |   | (101,842 | ) |
|                                                             |   |   |                                                      |   |   |                                                    |   |   |  |   |   |
| OTHER                INCOME (EXPENSES):                          |   |   |                                                 |   |   |                                               |   |   |   |   |   |
|                                                             |   |   |                                                 |   |   |                                               |   |   |   |   |   |   |   |
| Interest                expense-net                              |   |   | (88,272                                              | )      |   | (83,443                                            | )      |   | (168,257 | ) |   | (156,483 | ) |
| Interest                expense on beneficial conversion feature |   |   | (78,762                                              | )      |   | -                                                  |   |   | (85,140 | ) |   | - |   |
| Financing                costs                                   |   |   | (21,299                                              | )      |   | -                                                  |   |   | (42,599 | ) |   | - |   |
|                                                             |   |   |                                                 |   |   |                                               |   |   |   |   |   |   |   |
| Total                other income (expenses):                    |   |   | (188,333                                             | )      |   | -                                                  |   |   | (295,996 | ) |   | - |   |
|                                                             |   |   |                                                 |   |   |                                               |   |   |   |   |   |   |   |
| NET                LOSS TO COMMON STOCKHOLDERS                   |   | $      | (785,819                                             | )      | $      | (110,045                                           | )      | $ | (1,783,563 | ) | $ | (258,325 | ) |
|                                                             |   |   |                                                 |   |   |                                               |   |   |   |   |   |   |   |
| NET                LOSS PER SHARE:                               |   |   |                                                      |   |   |                                                    |   |   |  |   |   |  |   |
| BASIC                AND DILUTED                                 |   | $      | (0.02                                                | )      | $      | (0.00                                              | )      | $ | (0.06 | ) | $ | (0.01 | ) |
|                                                             |   |   |                                                 |   |   |                                               |   |   |   |   |   |   |   |
| WEIGHTED                AVERAGE NUMBER OF SHARES OUTSTANDING:    |   |   |                                                      |   |   |                                                    |   |   |  |   |   |  |   |
| BASIC                AND DILUTED                                 |   |   | 31,709,491                                           |   |   | 30,509,700                                         |   |   | 31,140,430 |   |   | 30,509,700 |   |

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS, INC.**

**STATEMENTS      OF CASH FLOWS**

**(Unaudited)**

|                                                                                                                                                                                                                                                                                                |   | **Six Months Ended June                30,** |       |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------------------------------|------------|
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |
|                                                                                                                                                                                                                                                                                                |   | **2005**                                                    |       | **2004** |   |
|                                                                                                                                                                                                                                                                                                |   | **(Restated)**                                              |       |   |   |
| OPERATING                ACTIVITIES:                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |  |   |
| Net                loss                                                                                                                                                                                                                                                                             |   | $                                                           | (1,783,563 | ) | $ | (258,325 | ) |
| Adjustments                to reconcile net loss to net cash (used in) operating                activities:                                                                                                                                                                                         |   |                                                        |       |   |   |   |   |
| Depreciation                and amortization                                                                                                                                                                                                                                                        |   |                                                        | 25,280     |   |   | 18,330 |   |
| Bad                debt expense                                                                                                                                                                                                                                                                     |   |                                                        | 51,982     |   |   | — |   |
| Amortization                of deferred costs                                                                                                                                                                                                                                                       |   |                                                        | 57,143     |   |   | 42,599 |   |
| Warrants                issued for recruiting services                                                                                                                                                                                                                                              |   |                                                        | 399,622    |   |   | — |   |
| Beneficial                conversion feature of convertible debentures                                                                                                                                                                                                                              |   |                                                        | 85,140     |   |   | — |   |
| Options                issued to employees as compensation                                                                                                                                                                                                                                          |   |                                                        | 553,309    |   |   | — |   |
| Changes                in assets and liabilities:                                                                                                                                                                                                                                                   |   |                                                        |       |   |   |   |   |
| Accounts                receivable                                                                                                                                                                                                                                                                  |   |                                                        | 143,594    |   |   | (64,385 | ) |
| Royalty                receivable                                                                                                                                                                                                                                                                   |   |                                                        | —    |   |   | 9,078 |   |
| Subscription                receivable                                                                                                                                                                                                                                                              |   |                                                        | —    |   |   | 2,000 |   |
| Inventories                                                                                                                                                                                                                                                                                         |   |                                                        | 13,060     |   |   | (41,899 | ) |
| Other                current assets                                                                                                                                                                                                                                                                 |   |                                                        | (23,426    | ) |   | (19,079 | ) |
| Accounts                payable, accrued payroll expense to officers and accrued                expenses                                                                                                                                                                                            |   |                                                        | 29,920     |   |   | 109,124 |   |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| Net                cash used in operating activities                                                                                                                                                                                                                                                |   |                                                        | (447,939   | ) |   | (202,557 | ) |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| CASH                FLOWS FROM INVESTING ACTIVITIES:                                                                                                                                                                                                                                                |   |                                                        |       |   |   |  |   |
| Purchases                of property and equipment                                                                                                                                                                                                                                                  |   |                                                        | (122,729   | ) |   | (225,132 | ) |
| Acquisitions                of patents and trademarks                                                                                                                                                                                                                                               |   |                                                        | (1,600     | ) |   | (11,270 | ) |
| Deferred                finance cost                                                                                                                                                                                                                                                                |   |                                                        | (160,000   | ) |   | — |   |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| Net                cash used in investing activities                                                                                                                                                                                                                                                |   |                                                        | (284,329   | ) |   | (236,402 | ) |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| CASH                FLOWS FROM FINANCING ACTIVITIES:                                                                                                                                                                                                                                                |   |                                                        |       |   |   |  |   |
| Cash                overdraft                                                                                                                                                                                                                                                                       |   |                                                        | (26,953    | ) |   | — |   |
| Proceeds                from shareholder loans                                                                                                                                                                                                                                                      |   |                                                        | 30,000     |   |   | 1,097,277 |   |
| Proceeds                from issuance of debentures                                                                                                                                                                                                                                                 |   |                                                        | 1,510,000  |   |   | — |   |
| Repayments                of shareholder loans                                                                                                                                                                                                                                                      |   |                                                        | (623,287   | ) |   | (678,540 | ) |
| Proceeds                from issuance of common stock                                                                                                                                                                                                                                               |   |                                                        | 2,000      |   |   | — |   |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| Net                cash provided by financing activities                                                                                                                                                                                                                                            |   |                                                        | 891,760    |   |   | 418,737 |   |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| NET                INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                                                                                                                                                                                                                                 |   |                                                        | 159,492    |   |   | (20,222 | ) |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| CASH                AND CASH EQUIVALENTS, BEGINNING OF PERIOD                                                                                                                                                                                                                                       |   |                                                        | 148,630    |   |   | 24,182 |   |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| CASH                AND CASH EQUIVALENTS, END OF PERIOD                                                                                                                                                                                                                                             |   | $                                                           | 308,122    |   | $ | 3,960 |   |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| SUPPLEMENTAL                DISCLOSURE OF NON-CASH FLOW INFORMATION:                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| During                the six month periods ended June 30, 2005 and 2004, the                previous year’s balance of                accrued interest of $228,773 and $68,265, respectively, for a                shareholder’s loan was added to the loan balance as principal. |   | $                                                           | 228,773    |   | $ | 68,265 |   |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| During                the six month period ended June 30, 2005, 1,000,000 shares of common                stock                were issued for a warrant conversion at $.01 per share. Payment due                of                $10,000 was offset to a note payable to this stockholder.       |   | $                                                           | 10,000     |   | $ | — |   |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| During                the six month period ended June 30, 2005, 1,100,000 options were                issued to                employees as compensation                                                                                                                                            |   | $                                                           | 952,500    |   | $ | — |   |
|                                                                                                                                                                                                                                                                                                |   |                                                        |       |   |   |   |   |
| During                the six month period ended June 30, 2005, debentures in the amount                of                $1,510,000 were sold and resulted in beneficial conversion charge                of                $1,510,000                                                             |   | $                                                           | 1,510,000  |   | $ | — |   |

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**NOTES        TO FINANCIAL STATEMENTS**

**(UNAUDITED)**

**June        30, 2005**

**1.      Description of Business/Basis of Presentation**

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,      INC.**

**NOTES      TO FINANCIAL STATEMENTS**

**(UNAUDITED)**

**June      30, 2005**

**2.**
**Substantial      Doubt Regarding Ability To Continue As A Going Concern**

**3.      Summary Of Significant Accounting Policies**

***Basis      of Presentation:***

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**NOTES        TO FINANCIAL STATEMENTS**

**(UNAUDITED)**

**June        30, 2005**

**3.      Summary Of Significant Accounting Policies (continued)**

**4.      Restatement**

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**NOTES        TO FINANCIAL STATEMENTS**

**(UNAUDITED)**

**June        30, 2005**

**4.      Restatement (Continued)**

|                                              |   | June                30, 2005 |        |
|---------------------------------------------------|--------|------------------------------|-------------|
|                                              |   | As                reported   |        | As                Restated |   |
| BALANCE                SHEET:                     |   |                         |        |   |   |   |   |
| Debentures                payable-net of discount |   | $                            | 1,510,000   |   | $ | 85,140 |   |
| Additional                paid-in capital         |   |                         | 43,553,856  |   |   | 44,945,978 |   |
| Less:                Deferred compensation        |   |                         | (1,061,006  | ) |   | (399,191 | ) |
| Accumulated                deficit                |   |                         | (44,924,775 | ) |   | (45,553,852 | ) |

|                                                             |   | For                the three months endedJune                30, 2005 |     | For                the six months endedJune                30, 2005 |   |
|------------------------------------------------------------------|--------|-----------------------------------------------------------------------|----------|---------------------------------------------------------------------|--------|
|                                                             |   | As                reported                                            |     | As                Restated                                          |   | As                reported |   | As                Restated |   |
| STATEMENT                OF OPERATIONS:                          |   |                                                                  |     |                                                                |   |   |   |   |   |   |   |   |   |
| Selling,                general and administrative expense       |   | $                                                                     | 428,215  |                                                                | $      | 633,070 |   | $ | 1,072,887 |   | $ | 1,616,824 |   |
| Loss                from operations                              |   |                                                                  | (392,631 | )                                                                   |   | (597,486 | ) |   | (943,630 | ) |   | (1,487,567 | ) |
| Interest                expense-net                              |   |                                                                  | (109,571 | )                                                                   |   | (88,272 | ) |   | (210,856 | ) |   | (168,257 | ) |
| Interest                expense on beneficial conversion feature |   |                                                                  | -        |                                                                |   | (78,762 | ) |   | - |   |   | (85,140 | ) |
| Financing                costs                                   |   |                                                                  | -        |                                                                |   | (21,299 | ) |   | - |   |   | (42,599 | ) |
| Net                loss to common shareholders                   |   |                                                                  | (502,202 | )                                                                   |   | (785,819 | ) |   | (1,154,486 | ) |   | (1,783,563 | ) |
| Earnings                per share                                |   |                                                                  | (.02     | )                                                                   |   | (.02 | ) |   | (.04 | ) |   | (.06 | ) |

|                                                                   |   | For                the six months endedJune                30, 2005 |       |
|------------------------------------------------------------------------|--------|---------------------------------------------------------------------|------------|
|                                                                   |   | As                reported                                          |       | As                Restated |   |
| STATEMENT                OF CASH FLOWS:                                |   |                                                                |       |   |   |   |   |
| Net                loss                                                |   | $                                                                   | (1,154,486 | ) | $ | (1,783,563 | ) |
| Warrants                issued for recruiting services                 |   |                                                                | 280,000    |   |   | 399,622 |   |
| Beneficial                conversion feature of convertible debentures |   |                                                                | -          |   |   | 85,140 |   |
| Options                issued to employee as compensation              |   |                                                                | -          |   |   | 553,309 |   |
| Amortization                of options granted employees               |   |                                                                | 128,994    |   |   | - |   |

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**NOTES        TO FINANCIAL STATEMENTS**

**(UNAUDITED)**

**June        30, 2005**

**4.      Restatement (Continued)**

|                                                                                                                                                                                                    |   | For                the three months endedJune 30, 2005  |     |  For                the six months endedJune 30, 2005 |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------|----------|------------------------------------------------------------|--------|
|                                                                                                                                                                                                    |   | As                Reported                                   |     | As                Restated                                 |   | As                Reported |   | As                Restated |   |
| Net                loss to common shareholders                                                                                                                                                          |   |                                                         |     |                                                       |   |   |   |   |   |   |   |   |   |
| As                reported                                                                                                                                                                              |   | $                                                            | (502,202 | )                                                          | $      | (785,819 | ) | $ | (1,154,486 | ) | $ | (1,783,563 | ) |
| Add:                Stock-based employee compensation expense included in reported net                loss,                net of related tax affects                                                   |   |                                                         | 120,084  |                                                       |   | 324,938 |   |   | 128,994 |   |   | 553,309 |   |
| Deduct:                Total stock-based employee compensation expense determined under                fair                value based method for all awards, net of related tax                affects |   |                                                         |     |                                                       |   |   |   |   |   |   |   |   |   |
|                                                                                                                                                                                                    |   |                                                         | (114,326 | )                                                          |   | (522,955 | ) |   | (122,838 | ) |   | (768,053 | ) |
| Pro                forma                                                                                                                                                                                |   | $                                                            | (496,444 | )                                                          | $      | (983,836 | ) | $ | (1,148,330 | ) | $ | (1,998,307 | ) |
|                                                                                                                                                                                                    |   |                                                         |     |                                                       |   |   |   |   |   |   |   |   |   |
| Basic                and diluted net loss per share                                                                                                                                                     |   |                                                         |     |                                                       |   |   |   |   |   |   |   |   |   |
| As                reported                                                                                                                                                                              |   | $                                                            | (0.02    | )                                                          | $      | (0.02 | ) | $ | (0.04 | ) | $ | (0.06 | ) |
| Pro                forma                                                                                                                                                                                |   |                                                         | (0.02    | )                                                          |   | (0.03 | ) |   | (0.04 | ) |   | (0.06 | ) |

**5.      Inventories**

|                          |   | **June                30, 2005** |       | December                31, 2004 |   |
|-------------------------------|--------|----------------------------------|------------|----------------------------------|--------|
|                          |   |                             |       |                             |   |
| Raw                materials  |   | **$**                            | **67,808** |                             | $      | 87,407 |   |
| Finished                goods |   |                             | **21,159** |                             |   | 14,620 |   |
|                          |   | **$**                            | **88,967** |                             | $      | 102,027 |   |

----

**STATSURE          DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,          INC.**

**NOTES          TO FINANCIAL STATEMENTS**

**(UNAUDITED)**

**June          30, 2005**

**6.      Accounts Receivable**

**7.      Equipment Under Construction**

**8.      Accrued Expenses**

|                                     |   |   |  **June                30, 2005** |   |   |  December                31, 2004 |   |
|------------------------------------------|--------|--------|----------------------------------------|--------|--------|----------------------------------------|--------|
|                                     |   |   |                                   |   |   |                                   |   |
| Accrued                interest          |   | **$**  | **168,256**                            |   | $      | 228,773                                |   |
| Accrued                legal expense     |   |   | **-**                                  |   |   | 112,500                                |   |
| Other                accrued liabilities |   |   | **17,094**                             |   |   | 14,808                                 |   |
|                                     |   | **$**  | **185,350**                            |   | **$**  | 236,081                                |   |

**9.      Geographic Area Information**

|                          |   | **For the three months****ended                June 30,** |        | **For                the six months****ended                June 30,** |   |
|-------------------------------|--------|--------------------------------------------------------------------------|-------------|------------------------------------------------------------------------|--------|
|                          |   |                                                                     |        |                                                                   |   |
|                          |   | **2005**                                                                 |        | 2004                                                                   |   | **2005** |   | 2004 |   |
|                          |   |                                                                     |        |                                                                   |   |   |   |   |   |
| United                States  |   | **$**                                                                    | **3,890**   |                                                                   | $      | 213,854 |   | **$** | **151,498** |   | $ | 347,820 |   |
| United                Kingdom |   |                                                                     | **148,906** |                                                                   |   | 112,661 |   |   | **229,404** |   |   | 208,000 |   |
| Africa                        |   |                                                                     | **22,248**  |                                                                   |   | 40,600 |   |   | **48,738** |   |   | 66,900 |   |
| Other                         |   |                                                                     | **1,490**   |                                                                   |   | 8,247 |   |   | **11,367** |   |   | 32,840 |   |
|                          |   |                                                                     |        |                                                                   |   |   |   |   |   |   |   |   |   |
|                          |   | **$**                                                                    | **176,534** |                                                                   | $      | 375,362 |   | **$** | **441,007** |   | $ | 655,560 |   |

**10.      Deferred Costs**

----

**STATSURE          DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,          INC.**

**NOTES          TO FINANCIAL STATEMENTS**

**(UNAUDITED)**

**June          30, 2005**

**11.      Debenture Payable**

**12.      Financing From Shareholders**

**13.      Shareholders’ Equity Transactions**

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**NOTES        TO FINANCIAL STATEMENTS**

**(UNAUDITED)**

**June        30, 2005**

**14.      Contingencies **

| Payments                Due by Period |   | Future                Payments |      |
|---------------------------------------|--------|--------------------------------|-----------|
| <1                year             |   | $                              | 162,344   |   |
| 1-3                years              |   |                           | 3,009,640 |   |
| 4th                year               |   |                           | 377,500   |   |
|                                  |   | $                              | 3,549,484 |   |

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**June        30, 2005**

**ITEM      2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF      OPERATION**

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**June        30, 2005**

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**June        30, 2005**

**CRITICAL      ACCOUNTING POLICIES AND ESTIMATES**

**Restatement      of Financial Statements**

|   | a) | to                account for the beneficial conversion feature on certain convertible                debentures issued using the effective interest                method. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b) | to                properly record the amount of compensation expense for 1,100,000                stock                options granted to certain employees for                the six month period ended June 30,                2005 |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c) | to                record the proper expense for warrants issued for services rendered                to the                Company which was previously                discounted. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a) | Subsequent                to the filing of form 10-QSB for the three and six months periods                ended                June 30, 2005, the Company determined that the filing did not reflect                a                beneficial conversion feature on 9% convertible debentures issued                in 2005                as required under EITF 98-5 “Accounting for Convertible Securities With                Beneficial Conversion Features or Contingently Adjustable Conversion                Ratios”, as amended by EITF 00-27 “Application of Issue No. 98-5 to                Certain Convertible Instruments”. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   | The                Company recorded a $1,510,000 debenture debt discount from the beneficial                conversion feature computation. This amount is limited to the proceeds                of                the convertible debt instrument in accordance with EITF 98-5. The                debenture debt discount is being amortized over the life of the debentures                with the unamortized discount of $1,424,860 being netted with the                gross                amount of the debenture payable of $1,510,000. The result of this                restatement was to reflect the sale of the debentures as additional                paid-in capital ($1,510,000) and to amortize the beneficial conversion                feature for the three and six month periods ended June 30, 2005 of                $78,762                and $85,140, respectively. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**June        30, 2005**

|  | b) | The                Company revalued options granted to employees using FASB Interpretation                No. 28, Accounting for Stock Appreciation Rights and Other Variable                Stock                Option or Award Plans, an interpretation of APB Opinions No. 15 and                No. 25                (“FIN 28”). The Interpretation clarifies the accounting for compensation                related to variable stock options and specifies that compensation                should                be measured at the end of each period as the amount by which the                quoted                market value of the shares of the Company’s common stock covered by a                grant, exceeds the option price or value specified under the plan                and                should be accrued as a charge to expense over the periods the employee                performs the related services. Changes in the quoted market value                should                be reflected as an adjustment of accrued compensation and compensation                expense in the periods in which the changes occur until the date                the                number of shares and purchase price, if any, are both known. As a                result,                the compensation charge for these options for the six months ended                June                30, 2005 has been restated to $553,309 from $128,994. In addition,                deferred compensation was reduced to $399,191 from $1,061,006. The                result                of this restatement was to increase compensation expense by $424,315                and                to reduce deferred compensation by $661,815 and accordingly to increase                additional paid-in capital by                $237,500. |
|--|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | c) | Further,                the Company also revalued warrants issued during the first quarter                2005 as                payment for services rendered for which the Company had used a 30%                discount for various restriction. This revaluation increased the                related                expense to $399,622 from $280,000. The Company accounts for warrants                granted to its non-employee consultants using the fair value cost                in                accordance with SFAS 123 and EITF No. 96-18, “Accounting for Equity                Instruments That Are Issued to Other Than Employees”. The fair value of                warrants granted was estimated on the date of grant using the                Black-Scholes option-pricing model with the following weighted-average                assumptions: expected volatility of 200.4%, risk-free interest rate                of                3.71% and expected life of 4.93 years for the six month period ended                June                30, 2005. The effect of this restatement was to increase expenses                and                additional paid-in capital by                $119,622. |
|--|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                              |   | June                30, 2005 |        |
|---------------------------------------------------|--------|------------------------------|-------------|
|                                              |   | As                reported   |        | As                Restated |   |
| BALANCE                SHEET:                     |   |                         |        |   |   |   |   |
| Debentures                payable-net of discount |   | $                            | 1,510,000   |   | $ | 85,140 |   |
| Additional                paid-in capital         |   |                         | 43,553,856  |   |   | 44,945,978 |   |
| Less:                Deferred compensation        |   |                         | (1,061,006  | ) |   | (399,191 | ) |
| Accumulated                deficit                |   |                         | (44,924,775 | ) |   | (45,553,852 | ) |

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**June        30, 2005**

|                                                             |   | For                the three months endedJune                30, 2005 |     | For                the six months endedJune                30, 2005 |   |
|------------------------------------------------------------------|--------|-----------------------------------------------------------------------|----------|---------------------------------------------------------------------|--------|
|                                                             |   | As                reported                                            |     | As                Restated                                          |   | As                reported |   | As                Restated |   |
| STATEMENT                OF OPERATIONS:                          |   |                                                                  |     |                                                                |   |   |   |   |   |   |   |   |   |
| Selling,                general and administrative expense       |   | $                                                                     | 428,215  |                                                                | $      | 633,070 |   | $ | 1,072,887 |   | $ | 1,616,824 |   |
| Loss                from operations                              |   |                                                                  | (392,631 | )                                                                   |   | (597,486 | ) |   | (943,630 | ) |   | (1,487,567 | ) |
| Interest                expense-net                              |   |                                                                  | (109,571 | )                                                                   |   | (88,272 | ) |   | (210,856 | ) |   | (168,257 | ) |
| Interest                expense on beneficial conversion feature |   |                                                                  | -        |                                                                |   | (78,762 | ) |   | - |   |   | (85,140 | ) |
| Financing                costs                                   |   |                                                                  | -        |                                                                |   | (21,299 | ) |   | - |   |   | (42,599 | ) |
| Net                loss to common shareholders                   |   |                                                                  | (502,202 | )                                                                   |   | (785,819 | ) |   | (1,154,486 | ) |   | (1,783,563 | ) |
| Earnings                per share                                |   |                                                                  | (.02     | )                                                                   |   | (.02 | ) |   | (.04 | ) |   | (.06 | ) |

|                                                                   |   | For                the six months endedJune                30, 2005 |       |
|------------------------------------------------------------------------|--------|---------------------------------------------------------------------|------------|
|                                                                   |   | As                reported                                          |       | As                Restated |   |
| STATEMENT                OF CASH FLOWS:                                |   |                                                                |       |   |   |   |   |
| Net                loss                                                |   | $                                                                   | (1,154,486 | ) | $ | (1,783,563 | ) |
| Warrants                issued for recruiting services                 |   |                                                                | 280,000    |   |   | 399,622 |   |
| Beneficial                conversion feature of convertible debentures |   |                                                                | -          |   |   | 85,140 |   |
| Options                issued to employee as compensation              |   |                                                                | -          |   |   | 553,309 |   |
| Amortization                of options granted employees               |   |                                                                | 128,994    |   |   | - |   |

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**June        30, 2005**

|                                                                                                                                                                                                    |   | For                  the three months ended June 30, 2005 |     |  For                the six months ended June 30, 2005 |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------|----------|-------------------------------------------------------------|--------|
|                                                                                                                                                                                                    |   | As                Reported                                |     | As                Restated                                  |   | As                Reported |   | As                Restated |   |
| Net                loss to common shareholders                                                                                                                                                          |   |                                                      |     |                                                        |   |   |   |   |   |   |   |   |   |
| As                reported                                                                                                                                                                              |   | $                                                         | (502,202 | )                                                           | $      | (785,819 | ) | $ | (1,154,486 | ) | $ | (1,783,563 | ) |
| Add:                Stock-based employee compensation expense included in reported net                loss,                net of related tax affects                                                   |   |                                                      | 120,084  |                                                        |   | 324,938 |   |   | 128,994 |   |   | 553,309 |   |
| Deduct:                Total stock-based employee compensation expense determined under                fair                value based method for all awards, net of related tax                affects |   |                                                      |     |                                                        |   |   |   |   |   |   |   |   |   |
|                                                                                                                                                                                                    |   |                                                      | (114,326 | )                                                           |   | (522,955 | ) |   | (122,838 | ) |   | (768,053 | ) |
| Pro                forma                                                                                                                                                                                |   | $                                                         | (496,444 | )                                                           | $      | (983,836 | ) | $ | (1,148,330 | ) | $ | (1,998,307 | ) |
|                                                                                                                                                                                                    |   |                                                      |     |                                                        |   |   |   |   |   |   |   |   |   |
| Basic                and diluted net loss per share                                                                                                                                                     |   |                                                      |     |                                                        |   |   |   |   |   |   |   |   |   |
| As                reported                                                                                                                                                                              |   | $                                                         | (0.02    | )                                                           | $      | (0.02 | ) | $ | (0.04 | ) | $ | (0.06 | ) |
| Pro                forma                                                                                                                                                                                |   |                                                      | (0.02    | )                                                           |   | (0.03 | ) |   | (0.04 | ) |   | (0.06 | ) |

**RESULTS      OF OPERATIONS**

**Revenues.**
** **

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**June        30, 2005**

**Cost      of products sold**

**Research      and development expenses:**
** **
** **

|   | · | the                Hema-Strip(TM) HIV test clinical                trials |
|--------|--------|---------------------------------------------------------------------------|

|   | · | the                preparation of documents for FDA                submissions |
|--------|--------|--------------------------------------------------------------------------------|

**Selling,      general and administrative expenses**

**Loss      from operations:**

**Other      expenses:**

**Income      taxes**
***.***

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**June        30, 2005**

**LIQUIDITY      AND CAPITAL RESOURCES**

|                                     |   | **June                30, 2005** |        | December                31, 2004 |   |
|------------------------------------------|--------|----------------------------------|-------------|----------------------------------|--------|
| Cash                and cash equivalents |   | **$**                            | **308,122** |                             | $      | 148,630 |   |
| Working                capital (deficit) |   |                             | **(82,349** | **)**                            |   | (506,511 | ) |

|   | · | Legal                and accounting costs |
|--------|--------|-------------------------------------------|

|   | · | Expenses                recorded for beneficial conversion features of convertible debt,                and |
|--------|--------|-------------------------------------------------------------------------------------------------------------|

|   | · | Stock                and warrant issuance costs |
|--------|--------|-------------------------------------------------|

|   | · | Consulting                expenses |
|--------|--------|------------------------------------|

|   | · | Payroll                expenses |
|--------|--------|---------------------------------|

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**June        30, 2005**

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**June        30, 2005**

| Payments                Due by Period |   | Future                Payments |      |
|---------------------------------------|--------|--------------------------------|-----------|
| <1                year             |   | $                              | 162,344   |   |
| 1-3                years              |   |                           | 3,009,640 |   |
| 4th                year               |   |                           | 377,500   |   |
|                                  |   | $                              | 3,549,484 |   |

----

**STATSURE      DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,      INC.**

**June      30, 2005**

**ITEM      3. CONTROLS AND PROCEDURES **

**EVALUATION      OF DISCLOSURE CONTROLS AND PROCEDURES**

**CHANGE      IN INTERNAL CONTROLS**

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**June        30, 2005**

**PART      II. OTHER INFORMATION**

**Item      1**
**.      LEGAL PROCEEDINGS**

**Item      2. **
**CHANGES      IN SECURITIES**

**ITEM      3. **
**DEFAULTS      UPON SENIOR SECURITIES**

**ITEM      4. **
**SUBMISSION      OF MATTERS TO A VOTE OF SECURITY HOLDERS**

**ITEM      5. **
**OTHER      INFORMATION**

----

**STATSURE        DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,        INC.**

**June        30, 2005**

**ITEM      6. EXHIBITS **

| **Exhibit** |         |                                                                                                                                                                                                                                                                                                                                                    |
|-------------|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|        |         |                                                                                                                                                                                                                                                                                                                                                    |
| 11          |    | Earnings                per share                                                                                                                                                                                                                                                                                                                       |
|        |         |
| 31.1        |    | Certification                of Chief                Executive Officer                required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities                Exchange                Act of 1934, as amended.                                                                                                                                 |
|        |         |
| 31.2        |    | Certification                of Chief                Financial Officer                required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities                Exchange                Act of 1934, as amended.                                                                                                                                 |
|        |         |
| 32.1        |    | Certification                of Chief                Executive Officer                required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities                Exchange                Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant                to Section 906 of the Sarbanes-Oxley Act of 2002.                |
|        |         |
| 32.2        |    | Certification                of Chief                Financial Officer                required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities                Exchange                Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant                to Section 906 of the Sarbanes-Oxley Act of                2002. |

----

**STATSURE          DIAGNOSTIC SYSTEMS, INC. FORMERLY SALIVA DIAGNOSTIC SYSTEMS,          INC.**

**June          30, 2005**

**SIGNATURES**

|   |   | **STATSURE DIAGNOSTIC              SYSTEMS, INC.**  |
|--------|--------|----------------------------------------------------------|
|   |   |                                                     |   |
|   |   | /s/              Steve M. Peltzman                  |   |
|   |   | Steve M. Peltzman                                   |   |
|   |   | Chief Executive Officer                             |   |
|   |   | (principal executive officer)                       |   |
|   |   |                                                     |   |
|   |   | /s/              Leo Ehrlich                        |   |
|   |   | Leo Ehrlich                                         |   |
|   |   | Chief Financial Officer                             |   |
|   |   | (principal                financial officer)        |   |

----